Cargando…
Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
PURPOSE: Erythropoietic protoporphyria (EPP), characterized by painful cutaneous photosensitivity, results from pathogenic variants in ferrochelatase (FECH). For 96% of patients, EPP results from coinheriting a rare pathogenic variant in trans of a common hypomorphic variant c.315–48T>C (minor al...
Autores principales: | Dickey, Amy K., Quick, Corbin, Ducamp, Sarah, Zhu, Zhaozhong, Feng, Yen-Chen A., Naik, Hetanshi, Balwani, Manisha, Anderson, Karl E., Lin, Xihong, Phillips, John E., Rebeiz, Lina, Bonkovsky, Herbert L., McGuire, Brendan M., Wang, Bruce, Chasman, Daniel I., Smoller, Jordan W., Fleming, Mark D., Christiani, David C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796935/ https://www.ncbi.nlm.nih.gov/pubmed/32873934 http://dx.doi.org/10.1038/s41436-020-00951-8 |
Ejemplares similares
-
A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria
por: Balwani, Manisha, et al.
Publicado: (2022) -
Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
por: Naik, Hetanshi, et al.
Publicado: (2019) -
How I treat erythropoietic protoporphyria and X-linked protoporphyria
por: Leaf, Rebecca Karp, et al.
Publicado: (2023) -
Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016) -
PB2562: STUDY DESIGN OF THE AURORA TRIAL: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA
por: Levy, Cynthia, et al.
Publicado: (2023)